[go: up one dir, main page]

AU2001239549A1 - Keratinocyte growth inhibitors and hydroxamic acid derivatives - Google Patents

Keratinocyte growth inhibitors and hydroxamic acid derivatives

Info

Publication number
AU2001239549A1
AU2001239549A1 AU2001239549A AU3954901A AU2001239549A1 AU 2001239549 A1 AU2001239549 A1 AU 2001239549A1 AU 2001239549 A AU2001239549 A AU 2001239549A AU 3954901 A AU3954901 A AU 3954901A AU 2001239549 A1 AU2001239549 A1 AU 2001239549A1
Authority
AU
Australia
Prior art keywords
acid derivatives
hydroxamic acid
growth inhibitors
keratinocyte growth
keratinocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239549A
Inventor
Koji Hashimoto
Shigeki Higashiyama
Takao Kiyoi
Hirosato Kondo
Hiroshi Kumihara
Kiriko Kurokawa
Masaaki Sawa
Minoru Yamamoto
Kazuya Yoshiizumi
Kohichiro Yoshino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of AU2001239549A1 publication Critical patent/AU2001239549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/62Isoquinoline or hydrogenated isoquinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001239549A 2000-03-24 2001-03-22 Keratinocyte growth inhibitors and hydroxamic acid derivatives Abandoned AU2001239549A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2000084126 2000-03-24
JP2000-84126 2000-03-24
JP2000-120430 2000-04-21
JP2000120430 2000-04-21
JP2000394983 2000-12-26
JP2000-394983 2000-12-26
PCT/JP2001/002251 WO2001070269A1 (en) 2000-03-24 2001-03-22 Keratinocyte growth inhibitors and hydroxamic acid derivatives

Publications (1)

Publication Number Publication Date
AU2001239549A1 true AU2001239549A1 (en) 2001-10-03

Family

ID=27342786

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239549A Abandoned AU2001239549A1 (en) 2000-03-24 2001-03-22 Keratinocyte growth inhibitors and hydroxamic acid derivatives

Country Status (3)

Country Link
US (1) US20030229113A1 (en)
AU (1) AU2001239549A1 (en)
WO (1) WO2001070269A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388475C (en) 2002-05-31 2009-12-08 Brantford Chemicals Inc. Preparation of chiral 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid and derivatives
MXPA04012932A (en) * 2002-06-26 2005-06-03 Japan Bioindustry Ass Novel azasugar derivative and drug containing the same as the active ingredient.
EP1574856A4 (en) 2002-12-20 2007-09-05 Shigeki Higashiyama Method of screening cell growth inhibitor and cell growth inhibitor
NZ587207A (en) 2008-02-01 2012-05-25 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
CN104870422B (en) 2012-10-31 2019-03-15 富士胶片富山化学株式会社 Amine derivatives or their salts
EP2996709B1 (en) 2013-05-15 2020-05-06 The Board of Trustees of the Leland Stanford Junior University Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing
JO3466B1 (en) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co Tetrahydropyridopyrazines modulators of gpr6

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
ATE187455T1 (en) * 1990-08-14 1999-12-15 Chugai Pharmaceutical Co Ltd METHOTREXATE DERIVATIVES WITH ANTIRHEUMATIC ACTIVITY
CA2200163A1 (en) * 1996-03-22 1997-09-22 Michael Robert Wiley Antithrombotic diamides
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6277885B1 (en) * 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US20030091568A1 (en) * 2000-04-07 2003-05-15 Jurgen Frey Inhibitors for the formation of soluble human CD23

Also Published As

Publication number Publication date
WO2001070269A1 (en) 2001-09-27
US20030229113A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2002227122A1 (en) Systems and methods for management of memory
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU4201799A (en) Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
AU3312100A (en) Hydroxamic and carboxylic acid derivatives
AU5991699A (en) Quinolizinones as integrin inhibitors
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
AU5634999A (en) Hydroxamic acid derivatives as proteinase inhibitors
AU2001255199A1 (en) Ceramide derivatives and method of use
AU2001233034A1 (en) Method for preparing alpha-sulfonyl hydroxamic acid derivatives
AU2001236052A1 (en) Urease inhibitors
AU2002211662A1 (en) Nf-kappab inhibitors
AU2001244596A1 (en) Indolylpyrrole derivatives and cell death inhibitors
AU4933000A (en) Hydroxamic and carboxylic acid derivatives
AU5213300A (en) 2-nh-pyridones and pyrimidones as mrs inhibitors
AU2001281799A1 (en) Benzamide derivatives and their use as apob-100 and mtp inhibitors
AU2001267416A1 (en) N-sulfonyl hydroxamic acid derivatives as inhibitors of cd 23
AU2001239549A1 (en) Keratinocyte growth inhibitors and hydroxamic acid derivatives
AU2002216223A1 (en) Preservation of cells
AU5690099A (en) Free radical inhibitors for quenching aqueous phase polymer growth and related methods
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2002239438A1 (en) 2,4-hexadienoic acid and derivatives as corrosion inhibitors
AU2001236718A1 (en) Bioreactor and related method
AU6992500A (en) Alphavbeta3 integrin inhibitors